Table 1.
HCV NS5A inhibitors currently in clinical trials.
| NS5A Inhibitor | Clinical Trial | Drug Combination | Status |
|---|---|---|---|
| Daclatasvir (BMS-790052) | Phase III completed | +Asunaprevir | Submitted for FDA approval [59,60] |
| +polymerase inhibitor (Sofosbuvir or VX-135) ± Protease inhibitor ± Ribavirin | Genotypes 1, 3, 4 Under investigation for use in HCV-HIV co-infected cohorts [61,62,63,64,65] |
||
| Ledipasvir (GS-5885) | Phase III completed | +Sofosbuvir | Approved by FDA for genotype 1 [66,67] |
| GS-5816 | Phase III | +Sofosbuvir | Genotypes 1,2,3,4,5,6 [68,69] |
| ACH-3102 | Phase II completed | +Sofosbuvir | Genotype 1 (≤8 weeks treatment) [70] |
| Samatasvir (IDX-719) | Phase II | +Simeprevir (protease inhibitor) ± TMC647055 (polymerase inhibitor) | Genotype 1, 4, 6 [71] |
| GSK2336805 | Phase II | + Simeprevir + PEG-IFN + Ribavirin | Genotype 1 or 4 [72] |
| PPI-668 | Phase II | + Faldeprevir (protease inhibitor) + B1207127 (polymerase inhibitor) | [73] |
| PPI-461 | Phase Ib completed | - | Genotype 1 [74] |
| TD-6450 | Phase I | - | Potent against genotype 1a [75,76] |
| JNJ-47910382 | Phase I | - | Asian genotype-1 [77] |